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Disease controla b s t r a c t
Foot-and-Mouth Disease serotype O circulated endemically in Ecuador for many years, with an upsurge
occurring in 2009. This manuscript describes retrospectively in vitro and in vivo laboratory studies to pre-
dict the field effectiveness of a commercial FMD vaccine to protect against the field strain, and explains
the key actions and epidemiological strategies followed by the country to control the disease.
The results established that the use of a good quality oil vaccine, manufactured with strains that were
isolated long ago: O1 Campos Br/58 and A24 Cruzeiro Br/55; combined with the correct epidemiological
strategies, are useful to control field strains when used in periodic biannual vaccination campaigns.
Published by Elsevier Ltd.1. Introduction
Foot-and-Mouth Disease (FMD) was first detected in Ecuador in
1956 as serotype A, then in 1962 the first outbreak of serotype O
occurred [1]. Historically, serotype A has had a sporadic presence
in the country, with its last detection being in 2002. Serotype O
has been endemic almost from its first incursion. Between 2000
and 2008, an average of 33 outbreaks associated with serotype O
were reported in Ecuador per year [2]. In 2009, an upsurge in the
occurrence of FMD took place across the country, with a peak of
109 outbreaks detected that year, as recorded with the Continental
FMD Surveillance System.1 The greatest peaks of outbreaks occurred
over the months of May and June, six-month after the previous vac-
cination cycle (November to mid-December).
The Veterinary Authority of Ecuador (VEA) requested technical
cooperation to PANAFTOSA to support their National FMD Eradica-
tion Program, particularly in assisting with the response to the
recent increase of FMD clinical cases. Lack of success in FMD con-
trol was attributed to a deficient employment of the FMD control
program. In particular this was due to a weakness of animal move-ment restrictions and a poor implementation of the vaccination
campaign. These two activities were mainly managed by the pri-
vate sector with poor regulation by the official authorities.
FMD vaccines in use in Ecuador are BEI inactivated with oil
adjuvant, and formulated with O1 Campos and A24 Cruzeiro strains.
Considering the relevance of vaccination to control the disease, it
was of paramount importance to verify to what extent the vaccine
strains currently used in Ecuador were capable of controlling the
disease outbreaks occurring in 2010. Upon performing in vitro
studies with the 2010 FMD field virus, as well as the epidemiolog-
ical analysis of the field situation in Ecuador; PANAFTOSA recom-
mended revaccination of the cattle population with the bivalent
commercial vaccine to control field outbreaks. In contrast, another
OIE FMD reference laboratory suggested the development of an
autologous vaccine as their recommendation [3]. Moreover, results
obtained by in vivo challenge were published indicating the lack of
appropriate protection of a monovalent O1 Campos experimental
vaccine against the field viruses circulating in Ecuador [4].
The VAE followed the recommendations from PANAFTOSA to
carry on a vaccination campaign using the former bivalent com-
mercial vaccine and incorporated a number of key actions and con-
trol strategies to progress in the FMD control.
The situation of opposing vaccine strain recommendations for
the control of a field virus described above is likely to be repeated
in the FMD scenarios worldwide. This study will help to contextu-
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demiological strategies when countries encounter similar situa-
tions upon decisions of which vaccine to use. This paper explains
the in vitro tests performed by PANAFTOSA, as well as the in vivo
challenge studies performed at PIADC by USDA. Additionally, the
paper describes the key actions taken by the VAE to fight against
the disease and the evolution of occurrence of FMD in the country.2. Materials and methods
2.1. Virus strains and typing
In September 2010, PANAFTOSA received and analyzed nine
vesicular epithelium samples previously identified as FMDV sero-
type O by the Ecuadorian laboratory. Virus typing was performed
by ELISA as previously described [5]. Field samples were processed
and passaged twice in BHK-21 Clone 13 cells and supernatants
were used for sequencing of the VP1 coding region and determina-
tion of the serological relationship (r1 value) by complement fixa-
tion [6]. A sample identified as 036-331 (r1 0.45), was collected on
June 4th, 2010 from a FMD outbreak which occurred in Orellana
Province in Ecuador (O/Orellana-036/ Ecuador 2010).This sample
was selected for further studies of r1 value and vaccine matching
tests. FMDV O1 Campos from the PANAFTOSA repository collection
was also used for determining the r1 value. Simultaneously, five
separate samples of tongue epithelium homogenates were
received in Plum Island Animal Disease Center (PIADC) for similar
purposes of serological, genetic and antigenic characterization of
the Ecuador 2010 field strains of FMDV, including the O/
Orellana-051-350/Ecuador 2010. All samples were fully character-
ized by virus isolation, real time RT-PCR, Ag ELISA and cross-
neutralization assays. All five specimens were directly sequenced
from the epithelial homogenate without adaptation to tissue cul-
ture to obtain the full-length nucleotide sequence of the protein
coding region (ORF).2.2. Nucleotide sequencing
For obtaining the VP1 sequences, the RNA extraction was per-
formed using Trizol reagent (Invitrogen) following the manufac-
turer’s protocol. PCR amplification and sequencing were
performed as described elsewhere [7]. For full ORF sequence of
O/Orellana-051-350/Ecuador 2010 the long distance cDNA and
overlapping PCR DNA fragments technique was used as described
in [8]. The purifiedmaterial was used for sequencing reaction using
the Big Dye Terminator kit 3.1 (Applied Biosystems) according to
manufacturer’s procedure. VP1 sequences were edited manually
and aligned using the program BioEdit, version 5.0.2.1. For the
full-length ORF sequence, the Sequencher software was used for
sequence assembly. Finally, for performing alignments and for
the comparative analysis of the sequences with those available in
GenBank, MEGA 6.0 software was used [9].2.3. Vaccines
For the in vivo cross protection study the conventional, com-
mercial BEI inactivated, water in oil, bivalent vaccine O1 Campos/
A24 Cruzeiro manufactured by VECOL in Colombia was used. For
the in vitro studies to predict the expectancy of protection by EPP
calculation, the bovine sera panels used were prepared with con-
ventional, water in oil, trivalent vaccine O1 Campos/A24 Cruzeiro/
C3 Indaial, BEI inactivated and manufactured by PANAFTOSA.2.4. Determination of serological relationship ‘‘r1”
The r1 value was used to estimate the antigenic relatedness of
the vaccine O1 Campos strain and the field isolate. The reciprocal
serum titer against heterologous virus/reciprocal serum titer
against homologous virus was determined by complement fixation
test (CF) [6] and virus neutralization (VN) assays. CF was per-
formed in tubes as previously described [10] using guinea pig
FMDV O1 Campos antisera. One dimensional microplate neutral-
ization tests were performed as previously described [11]. Briefly,
a virus preparation containing 2000 tissue culture infectious
doses/mL was mixed volume to volume with serial dilutions of
sera. Mixtures were incubated for 1 h at 37 C and then 100 lL of
each mixture was inoculated into four wells each in microplates
with BHK-21 C13 cell monolayers. A bovine sera panel composed
of cattle sera collected 30 days post vaccination (dpv) and 30 days
post booster vaccination (dpr), with a trivalent commercial vac-
cine, were analyzed by VN against vaccine and field strains. Anti-
body titers were calculated as the log10 of the reciprocal
antibody dilution required for 50% neutralization (TCID50%).
2.5. Assessment of expectancy of protection (EPP)
Sera panels from 30 vaccinated cattle or 30 revaccinated cattle
were used to estimate the protection offered by the vaccine against
the field virus by the EPP (likelihood that vaccinated cattle would
be protected against a challenge of 10,000 bovine infective doses
of virus) [12,13]. The EPPs were determined by using the liquid
phase blocking ELISA (LPBE) and the VN assays. LPBE tests were
carried out according to the method previously described [10]. Sera
panels were titrated in ELISA against FMDV O1 Campos and FMDV
field strain O/Orellana-036/ Ecuador 2010. Titers were expressed
as log10 of the reciprocal sera dilution giving an OD value equal
to the 50% of mean OD value of antigen control. The VN assay
was performed as described above and a group of 10 revaccinated
cattle sera were used to estimate the EPP. The EPP value for each
individual serum was obtained using the EPP table generated by
PANAFTOSA (table available upon request). A mean of individual
EPPs was then calculated.
2.6. Cross protection experiment
The protection induced by the bivalent O1 Campos, A24 Cruzeiro
vaccine against a serotype O/Orellana-051-350/Ecuador 2010 field
strain was tested by protection against generalized foot infection
(PGP) [14]. Twenty-two Holstein cross-bred steers 300–400 lb,
were housed in a large animal room in the BL3 Ag facilities at
PIADC. All animals were tested free of FMDV antibodies. All proce-
dures were conducted humanely according to the NIH Guide for
the Care and Use of Laboratory Animals and preapproved by the
institutional animal care and use committee. The bovines were
randomly distributed in three different groups and challenged after
either single vaccination or double vaccination. Group 1: (10 bovi-
nes) received one full dose of vaccine (2.0 mL) at day 0 and another
2.0 mL booster dose 14 days later. Group 2: (10 bovines) received
one full dose of vaccine (2.0 mL) on the same day group 1 received
the booster dose. Group 3: (2 bovines) were the unvaccinated con-
trol animals. All of the bovines comingled in the same room for the
duration of the experiment. The vaccine used in this experiment
was a conventional, commercial water in oil, bivalent vaccine O1
Campos/A24 Cruzeiro similar, but a different production batch,
from the FMD vaccine that was used in the outbreak area in Ecua-
dor. The EPP for the O1 Campos strain was performed by the
Colombian vaccine regulatory authorities resulting in 89.9% EPP.
The challenge virus was derived from tongue epithelium sample
051-350, collected in the province of Orellana Ecuador in 2010
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twice in bovine tongue and a final challenge stock was prepared
from the vesicular fluid collected. The titer was calculated by ton-
gue titration in cattle. All bovines were challenged on the same
day, group 1 on 21 days post revaccination, group 2 on 21 days
post vaccination. Challenge was done by intradermal inoculation
in four different sites on the tongue, with a total of 10,000 BID50.
Animals were observed under xylazine sedation at 7 and 14 days
post challenge (dpc). Animals were considered protected when
no vesicular lesions were detected in their feet.
2.7. Key actions and control strategies
During the FMD outbreaks in 2010 and 2011, the VEA estab-
lished a control strategy to attend all the suspicions, quarantine
the affected herds and areas with movement restrictions, and fun-
damentally undertook ring vaccination around all the detected
foci. In 2011, PANAFTOSA facilitated technical cooperation with
Ecuador leading to actions being taken at the managerial level to
empower the VAE, particularly the National FMD Eradication Pro-
gram, to perform the activities necessary to eliminate outbreaks.
Thus, the FMD control program was reviewed giving responsibility
to the VEA in actions directed to FMD control. There was also an
improvement in the written guidelines to explain the strategies
and actions to detect, follow, and control FMD outbreaks in the
field, as well as a reinforcement of the control of animal movement
with the incorporation of targeted surveillance strategies to high
risk premises. Control of the vaccination campaign was placed
under the supervision of the VAE, who strengthened the execution
of the biannual vaccination campaigns in cattle of all ages and
implemented a strategic additional vaccination targeting young
animals.3. Results
3.1. Virus typing and r1 value
Field samples were typed as FMDV O1 by Ag ELISA and con-
firmed by VP1 sequence analysis. The r1 values obtained by CF50%
ranged between 0.35 and 0.71, half of the samples having r values
between 0. 45 and 0.49 (n = 8). Strains within this range of values
were considered as the most representative of the field situation. A
sample identified as 036-331 (r1 0.45), collected on June 4th, 2010
from a FMD outbreak in Orellana Province in Ecuador (O/Orellana-
036/Ecuador 2010), was selected for further VN studies of r1 value
and vaccine matching tests. The average r1 values determined by
VN test with sera from 30 dpv cattle was 0.158 and with sera from
30 dpr cattle was 0.241.
3.2. Sequencing
Both VP1 and complete ORF nucleotide sequencing demon-
strated 98% or greater nucleotide identity between all of the O
Ecu 2010 isolates and 100% identity in amino acid sequences.
The strain circulating in Ecuador was 91% identical at nucleotide
level to the previously published O1 Campos sequence
(AY593819). The main differences were observed in the G-H loop
of VP1, with nucleotides deletion which translates to the loss of
two amino acids next to the RGD motif of this protein (Fig. 1).
Additionally, a double deletion in the coding region corresponding
to the host-range related protein 3A, amino acid positions 1565
and 1566, of the ORF was observed (Fig. 2).
A 100% identity was recognized when comparing the VP1
nucleotide sequence from O/Orellana-036/ Ecuador 2010 (Gen-
Bank Accession Number KX274464, used for the in vitro EPP vac-cine matching) and O/Orellana-051-350/Ecuador 2010 (GenBank
Accession Number KX35623, used for the in vivo cross protection
test).
3.3. Expectancy of protection (EPP)
EPP values of 47.85 and 91.40 on the panel of bovine sera were
obtained when tested against the Ecuador field virus in the LPBE
for 30 dpv and 30 dpr sera respectively. In the VN assay an EPP
value of 99.98 was obtained with sera from 30 dpr.
3.4. Cross protection experiment
Clinical evaluation for FMD lesions was performed at 7 and
14 dpc. Unvaccinated control bovines showed lesions in tongue
and all four feet at the clinical evaluation at 7 dpc (Table 1). No
lesions were found in the feet of bovines in group 1 at 7 dpc, and
a single lesion was found on 1 foot of one animal in this group at
14 dpc. Nine out of ten (90%) of the revaccinated bovines were pro-
tected against feet generalization at the final clinical evaluation.
Fifty percent of bovines that received a single vaccination were
protected against feet generalization and only two of them showed
generalization in all four feet (Table 1).
3.5. Evolution of FMD in Ecuador (2009–2015)
After the peak of 109 FMD outbreaks in 2009, there was a
reduction in 2010 with 42 outbreaks. In response to the outbreak
control actions implemented by the VAE a further drop was
observed in 2011, with only five outbreaks detected. Since then,
no more cases of FMD occurred, with the date of last occurrence
being August 2011. The country is currently FMD free and on
May 2015 the OIE General Assembly endorsed the recognition of
FMD free with vaccination in continental Ecuador and FMD free
without vaccination for the Galápagos Islands.4. Discussion
The results of this report, as well as the recent evaluation of
FMD in Ecuador (including its FMD-free international recognition)
supports the PANAFTOSA’s rationale that the implementation of a
vaccination program, using vaccines with appropriate strains and
of good quality, likewise an effective control of animal movement,
are key issues for the success in controlling the disease. Therefore,
we demonstrate here that development of a new vaccine was not
necessary for Ecuador in 2010. The development of a new vaccine
strain is a lengthy and costly process and the decision of including
new strains in vaccine formulations should consider experimental
and epidemiological observations. Despite the evidence on the
genetic evolution of FMD strains circulating in Ecuador over the
years we demonstrated here the capability of the vaccine in use
to protect cattle against the disease. Therefore, we propose that
implementing adequate vaccination practices is critical to obtain
satisfactory protective response against infection with the O/
ECU/2010 field strain. Proper protection would only be achieved
through adequate vaccine quality control, controlled application
conditions such as systematic vaccination campaigns, and good
practices of the vaccination program.
There are many examples in literature of the problems encoun-
tered by other authors in correlating vaccine coverage in vivo with
in vitro ‘‘r1”values [15–18] and it was also observed in this study.
Our VN derived ‘‘r” values were definitively in the low range of
the predictive scale for protection (between 0.1 and 0.2) which
did not mirrored the situation after vaccination in the field. In
the past considering the problems observed with vaccine matching
Fig. 1. Amino acid deletion observed next to RGD motif in the FMDV strains from Ecuador.
Fig. 2. Amino acid deletions observed in protein 3A in the FMDV strain from Ecuador.
Table 1
Distribution of vaccinated groups, clinical score and protection against generalized
foot infection after challenge with 10,000 BID50 of O/Orellana-051-350/Ecuador 2010
virus.
Vaccination Animal
identification
number
Clinical
score*
7 dpc**
Clinical
score*
14
dpc**
Protection
(%)
Group
1
Vaccination at
0 days booster
at 14 days
25 0 0 90
26 0 0
27 0 0
28 0 0
29 0 1
30 0 0
31 0 0
32 0 0
33 0 0
34 0 0
Group
2
Single
vaccination
35 4 4 50
36 1 1
37 0 0
38 0 0
39 0 0
40 0 0
41 1 1
42 4 4
43 0 0
44 2 2
Group
3
Unvaccinated 45 4 4
46 4 4
* Clinical score based on number of affected feet.
** Days post challenge.
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EPP approach to choose the appropriate vaccine viral strain, based
on the correlation between antibody titers in vaccinated animals
and protection against challenge. The methodology has being
applied with success during the last 3 decades. The EPP results
reported here closely correlates with results of the in vivo chal-
lenge experiments, which is still considered the gold standard for
vaccine matching. This result is in clear contrast with previously
published data [4]. These authors showed only 6% and 18% protec-
tion after single and booster vaccination respectively, and claimed
that their O1 Campos vaccine lacked protection against the 2010
field strains from Ecuador.
The success in the control of FMD in South America has been
achieved by biannual vaccination using oil vaccine manufactured
with strains that were isolated long ago: A24 Cruzeiro/55, O1 Cam-pos/58, and in some countries also C3 Indaial/71. This is an exam-
ple of how stable the immune protection is, which is provided by
old strains, despite the continuous generation of new genetic vari-
ants in the field. Such observation strongly suggests that good
management practices and good quality vaccines are extremely
important when used in periodic biannual vaccination campaigns.5. Conclusion
This report provides a retrospective analysis of the last occur-
rence of FMD in Ecuador, the control actions implemented, and
their results. It concludes that the application of vaccination cam-
paigns and sanitary measures were effective in controlling the
FMD situation in Ecuador, leading to a subsequent suppression of
viral circulation throughout the country. In particular, the epidemi-
ological data demonstrates the effectiveness of the use of the com-
mercial vaccines formulated with regionally standardized strains
and administrated in the framework of an eradication program
strengthened under the concept of good practice. The experience
described in this report proves how important it is to consider
the laboratory results, together with field-epidemiological infor-
mation, on the decision-making to choose the vaccine, particularly
in cases of emergency.Conflicts of Interest
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